References: 1. Iglarz M, Binkert C, Morrison K, et
al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin
receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736-745. 2.
Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic
interventions for patients with pulmonary arterial hypertension.
Circulation. 2014;130(24):2189-2208. 3. OPSUMIT® [package insert].
South San Francisco, CA: Actelion Pharmaceuticals US, Inc.
References: 1. Sitbon O, Morrell N. Pathways in pulmonary
arterial hypertension: the future is here. Eur Respir Rev.
2012;21(126):321-327. 2. OPSUMIT® [package
insert]. South San Francisco, CA:
Actelion Pharmaceuticals US, Inc. 3. Pulido T, Adzerikho I, Channick RN, et
al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary
arterial hypertension. N Engl J Med. 2013;369(9):809-818. 4.
McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary
hypertension. J Am Coll Cardiol. 2013;62(25)(suppl):D73-D81.
References: 1. OPSUMIT®
[package insert]. South San
Francisco, CA: Actelion Pharmaceuticals US, Inc. 2. Sitbon O, Morrell N.
Pathways in pulmonary arterial hypertension: the future is here. Eur Respir
Rev. 2012;21(126):321-327. 3. Humbert M, Lau EM, Montani D, Jaïs X,
Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with
pulmonary arterial hypertension. Circulation. 2014;130(24):2189-2208.
4. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the
diagnosis and treatment of pulmonary hypertension. Eur Respir J.
2015;46(4):903-975. 5. Hayes GB. Pulmonary Hypertension: A Patient’s
Survival Guide. 5th ed. Silver Spring, MD: Pulmonary Hypertension
Association; 2012. 6. Ryan JJ, Archer SL. The right ventricle in pulmonary
arterial hypertension: disorders of metabolism, angiogenesis and adrenergic
signaling in right ventricular failure. Circ Res. 2014;115(1):176-188.
7. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients
with pulmonary arterial hypertension in the United States: how REVEAL differs from
historic and non-US Contemporary Registries. Chest. 2011;139(1):128-137.
8. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical
classification of pulmonary hypertension. J Am Coll Cardiol.
2013;62(25)(suppl):D34-D41.
References: 1. Galiè N, Humbert M, Vachiery JL,
et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary
hypertension. Eur Respir J. 2015;46(4):903-975. 2. Hoeper MM,
Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension.
J Am Coll Cardiol. 2013;62(25)(suppl):D42-D50. 3. Connolly HM, Oh
JK. Echocardiography. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's
Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia,
PA: Elsevier Saunders; 2012:200-276. 4. Pagana KD, Pagana TJ. Mosby's
Diagnostic and Laboratory Test Reference. 6th ed. St. Louis, MO: Mosby, An
Affiliate of Elsevier Science; 2003.
Reference: 1. OPSUMIT®
[package insert]. South San
Francisco, CA: Actelion Pharmaceuticals US, Inc.
References: 1. Galiè N, Humbert M, Vachiery JL, et al.
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
Eur Respir J. 2015;46(4):903-975. 2. OPSUMIT® [package insert]. South
San Francisco, CA: Actelion Pharmaceuticals US, Inc. 3. Humbert M, Lau EM,
Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for
patients with pulmonary arterial hypertension. Circulation.
2014;130(24):2189-2208.
